Characterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in diabetic db/db mice - 19/12/20
páginas | 10 |
Iconografías | 5 |
Vídeos | 0 |
Otros | 0 |
Graphical abstract |
Highlights |
• | Paired analysis of gut segmental bacterial composition and host gene expression was performed in rosiglitazone-treated diabetic db/db mice. |
• | Long-term rosiglitazone treatment promoted gut segment-specific changes in host gene expression without influencing gut bacterial composition. |
• | Rosiglitazone markedly affected transcriptional markers of host intestinal lipid metabolism and immune regulation. |
• | Local intestinal PPAR-γ signaling may potentially contribute to the metabolic effects of rosiglitazone. |
Abstract |
The gut microbiota has been implicated in the therapeutic effects of antidiabetics. It is unclear if antidiabetics directly influences gut microbiome-host interaction. Oral peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists, such as rosiglitazone, are potent insulin sensitizers used in the treatment of type 2 diabetes (T2D). PPAR-γ is abundantly expressed in the intestine, making it possible that PPAR-γ agonists directly influences gut microbiome-host homeostasis. The presented study therefore aimed to characterize local gut microbiome and intestinal transcriptome responses in diabetic db/db mice following rosiglitazone treatment. Diabetic B6.BKS(D)-Leprdb/J (db/db) mice (8 weeks of age) received oral dosing once daily with vehicle (n = 12) or rosiglitazone (3 mg/kg, n = 12) for 8 weeks. Gut segments (duodenum, jejunum, ileum, caecum, and colon) were sampled for paired analysis of gut microbiota and host transcriptome signatures using full-length bacterial 16S rRNA sequencing and RNA sequencing (n = 5–6 per group). Treatment with rosiglitazone improved glucose homeostasis without influencing local gut microbiome composition in db/db mice. In contrast, rosiglitazone promoted marked changes in ileal and colonic gene expression signatures associated with peroxisomal and mitochondrial lipid metabolism, carbohydrate utilization and immune regulation. In conclusion, rosiglitazone treatment markedly affected transcriptional markers of intestinal lipid metabolism and immune regulation but had no effect on the gut microbiome in diabetic db/db mice.
El texto completo de este artículo está disponible en PDF.Abbreviations : DEG, HbA1c, OGTT, PCA, PCoA, PPAR-γ, rRNA, TZD, T2D
Keywords : Peroxisome proliferator-activated receptor-γ, Diabetes, Mouse model, Gut microbiome, Gut transcriptome, Gut segment
Esquema
Vol 133
Artículo 110966- janvier 2021 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?